The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages

Arora P, Zhang L, Nehlmeier I, Kempf A, Cossmann A, Dopfer-Jablonka A, Schulz SR, Jäck HM, Behrens GM, Pöhlmann S, Hoffmann M (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Lancet Infectious Diseases Elsevier: Lancet

Book Volume: 22

Pages Range: 1665-1666

Journal Issue: 12

DOI: 10.1016/S1473-3099(22)00693-4

Authors with CRIS profile

Hans-Martin Jäck Department of Molecular Immunology

Involved external institutions

Deutsches Primatenzentrum (DPZ), Leibniz-Institut für Primatenforschung DE Germany (DE) Georg-August-Universität Göttingen DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE)

How to cite

APA:

Arora, P., Zhang, L., Nehlmeier, I., Kempf, A., Cossmann, A., Dopfer-Jablonka, A.,... Hoffmann, M. (2022). The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages. Lancet Infectious Diseases, 22(12), 1665-1666. https://doi.org/10.1016/S1473-3099(22)00693-4

MLA:

Arora, Prerna, et al. "The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages." Lancet Infectious Diseases 22.12 (2022): 1665-1666.

BibTeX: Download